AB Science – Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)

PRESS RELEASE

CLARIFICATION FOLLOWING THE FEBRUARY 11, 2022 PUBLIC HEARING OF THE ENFORCEMENT COMMITTEE OF THE FRENCH MARKET REGULATOR (AMF)

Paris, 12 February, 2022, 8.30pm CET

AB Science SA (Euronext – FR0010557264 – AB) needs to offer the next clarifications, following press articles revealed after the general public listening to of the Enforcement Committee of the French market regulator (AMF) on Friday, February 11, 2022.

As indicated within the Firm’s annual report, the AMF opened in September 2017 an investigation referring to the monetary info and the marketplace for AB Science shares. Following this investigation, AB Science and its CEO Alain Moussy obtained a press release of objections within the first quarter of 2021.

Following this assertion of objections, and as required by the process, a Rapporteur was then appointed by the Enforcement Committee. The Rapporteur drew up an impartial report on the investigation, each incriminating and exculpatory.

The AMF Enforcement Committee met on February 11, 2022 to listen to the place of its Rapporteur, the opinion of the AMF’s investigating group, and the events.

The AMF investigating group upheld the complaints towards (i) AB Science for not having communicated to the market in a well timed method what it thought-about to be privileged info referring to the advertising authorization process for masitinib in mastocytosis as of March 7, 2017, and (ii) Alain Moussy for having used such privileged info to promote a part of his shares, and requested monetary penalties.

AB Science and Alain Moussy have firmly and particularly contested these allegations.

The Rapporteur of the Enforcement Committee, on the idea of her report, thought-about that such privileged info didn’t exist on the time of the fundraising carried out by AB Science on March 24 and 27, 2017 and of the sale by Alain Moussy on March 31, 2017.

The choice of the Enforcement Committee is anticipated in 4 to 6 weeks.

Story continues

AB Science stays assured within the arguments it submitted to the Enforcement Committee and awaits the Committee’s choice.

About AB Science
Based in 2001, AB Science is a pharmaceutical firm specializing within the analysis, growth and commercialization of protein kinase inhibitors (PKIs), a category of focused proteins whose motion are key in signaling pathways inside cells. Our packages goal solely ailments with excessive unmet medical wants, usually deadly with brief time period survival or uncommon or refractory to earlier line of therapy.
AB Science has developed a proprietary portfolio of molecules and the Firm’s lead compound, masitinib, has already been registered for veterinary drugs and is developed in human drugs in oncology, neurological ailments, inflammatory ailments and viral ailments. The corporate is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Additional info is out there on AB Science’s web site:
www.ab-science.com.

Ahead-looking Statements – AB Science
This press launch incorporates forward-looking statements. These statements are usually not historic info. These statements embody projections and estimates in addition to the assumptions on which they’re based mostly, statements based mostly on tasks, aims, intentions and expectations concerning monetary outcomes, occasions, operations, future providers, product growth and their potential or future efficiency.

These forward-looking statements can usually be recognized by the phrases “count on”, “anticipate”, “consider”, “intend”, “estimate” or “plan” in addition to different related phrases. Whereas AB Science believes these forward-looking statements are cheap, traders are cautioned that these forward-looking statements are topic to quite a few dangers and uncertainties which might be tough to foretell and customarily past the management of AB Science and which can indicate that outcomes and precise occasions considerably differ from these expressed, induced or anticipated within the forward-looking info and statements. These dangers and uncertainties embody the uncertainties associated to product growth of the Firm which will not be profitable or to the advertising authorizations granted by competent authorities or, extra typically, any elements which will have an effect on advertising capability of the merchandise developed by AB Science, in addition to these developed or recognized within the public paperwork revealed by AB Science. AB Science disclaims any obligation or endeavor to replace the forward-looking info and statements, topic to the relevant laws, specifically articles 223-1 et seq. of the AMF Common Laws.

For extra info, please contact:

AB Science
Monetary Communication & Media Relations
traders@ab-science.com

Media Relations – USA

RooneyPartners
Kate Barrette
kbarrette@rooneypartners.com

+1 212 223 0561

Media Relations – France

NewCap
Arthur Rouillé
arouille@newcap.fr

+33 (0)1 44 71 00 15

Attachment